Senti Biosciences (SNTI) Net Income towards Common Stockholders (2021 - 2025)
Senti Biosciences' quarterly Net Income towards Common Stockholders came in at -$18.5 million in Q4 2025, down 2.28% quarter-over-quarter from -$18.1 million in Q3 2025.
Senti Biosciences has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$18.5 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders changed N/A year-over-year to -$18.5 million; the trailing twelve-month figure through Dec 2025 stood at -$65.5 million (down 25.55% YoY), and the FY2025 full-year result was -$67.9 million, changed N/A from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$18.5 million, down from -$18.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $21.7 million in Q3 2023, with the low at -$28.9 million in Q3 2024.
- Average Net Income towards Common Stockholders over 5 years is -$9.2 million, with a median of -$11.2 million recorded in 2024.
- Year-over-year, Net Income towards Common Stockholders slumped 997692.87% in 2022 and soared 1028.2% in 2023.
- Tracing SNTI's Net Income towards Common Stockholders over 5 years: stood at -$3.9 million in 2021, then plunged by 121.54% to -$8.5 million in 2022, then surged by 99.67% to -$28000.0 in 2023, then sank by 102992.86% to -$28.9 million in 2024, then jumped by 35.78% to -$18.5 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$18.5 million (Q4 2025), -$18.1 million (Q3 2025), and -$14.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.54 Mn |
| Sep 30, 2025 | -18.13 Mn |
| Jun 30, 2025 | -14.73 Mn |
| Mar 31, 2025 | -14.11 Mn |
| Sep 30, 2024 | -28.87 Mn |
| Jun 30, 2024 | -11.20 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -28,000.00 |
| Sep 30, 2023 | 21.69 Mn |
| Jun 30, 2023 | -4.45 Mn |
| Mar 31, 2023 | -4.87 Mn |
| Dec 31, 2022 | -8.55 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -21.74 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -3.86 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -8.99 Mn |
| Mar 31, 2021 | -1,178.00 |